Search
Rivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalFDA approved on July 1, 2011. … Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary.
Categories: Factor Xa Inhibitors, Direct factor Xa inhibitorsProducts: RIVAROXABAN DR. REDDY'S, Rivaroxaban 1A Pharma 10 mg – FilmtablettenPyridoxine
go.drugbank.com/drugs/DB00165ApprovedInvestigationalNutraceuticalVet approvedAs its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for normal functioning of many biological systems within the body. … Vitamin B6, principally in its biologically active coenzyme form pyridoxal 5'-phosphate, is involved in a wide range of biochemical reactions, including the metabolism of amino acids and glycogen, the
Mixtures: Daily Energy Brand B-complex, Doctor's Choice Brand for MenSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigational[L30598] An extended-release oral suspension formulation of sodium oxybate for narcolepsy, marketed under the brand name LUMRYZ, gained tentative FDA approval in July 2022 [L42645] and was fully approved … [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries.
Bepotastine
go.drugbank.com/drugs/DB04890ApprovedThe opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. … Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand
Axicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalIt is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults. … The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer.
Butriptyline
go.drugbank.com/drugs/DB09016ApprovedWithdrawnButriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.
Tirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … [L41820] Later, it was approved under a different brand name ZEPBOUND on November 8, 2023, for the chronic weight management in adults with obesity or overweight with at least one weight-related condition
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23).
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.